U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT
U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT
批准号:
6626364
负责人:
DAVID M. MARGOLIS
金额:
$138.08万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-01-01 至 2004-12-31
关键词:
AIDS AIDS /HIV neuropathy AIDS related neoplasm /cancer AIDS therapy HIV infections Histoplasma Mycobacterium avium Mycobacterium tuberculosis Pneumocystis pneumonia antiAIDS agent antiviral antibody body composition cardiovascular disorder cardiovascular disorder prevention clinical research clinical trial phase I cooperative study cytomegalovirus drug adverse effect drug interactions experimental designs gender difference glucose metabolism hepatitis B virus group hepatitis C virus human immunodeficiency virus 1 human subject human therapy evaluation hydroxyurea immunoregulation immunotherapy latent virus infection lipid metabolism longitudinal human study nucleoside analog nucleotide analog nutrition opportunistic infections outcomes research pathologic process pharmacokinetics prodrugs protease inhibitor statistics /biometry therapy compliance
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (adapted from applicant's abstract): The scientific focus of the
University of Texas Southwestern Medical Center AIDS Clinical Trials Unit
(UTSMC ACTU) will be on the immunopathogenesis of HIV infection and immune
reconstitution of patients treated with HAART. Specific areas of expertise
include the role of the adult thymus in immune reconstitution of patients on
HAART, the role of HIV-specific CD4+ and CD8+ T cell responses in the control
of HIV replication in patients who are, and are not, treated for HIV
infection, and the role of immune activation in HIV immunopathogenesis. In
addition, investigators at UTSMC ACTU have extensive expertise in
lipodystrophies, which they will bring to the study of protease
inhibitor-induced lipodystrophy. Given the strengths in both clinical and
basic science, they feel that the proposed UTSMC ACTU will serve as an
integral part of the AACTG's mission to develop novel and effective treatments
for HIV infection through a better understanding of the mechanisms underlying
the pathogenesis of HIV-induced illness. The overall goal of the UTSMC ACTU
will be to contribute to the mission of the AACTG. This will involve the
enrolling and retention of appropriate patients into clinical trials developed
within the framework of the AACTG. These patients will include all members of
the diverse population served by the clinical facilities. More importantly,
they envision being active participants in the scientific research agenda of
the AACTG, and will contribute substantially to its knowledge base and future
direction. In order to complete this goal, the specific aims of the UTSMC
ACTU will be: (1) to contribute to the HIV disease research agenda; (2) to
contribute to the complications of HIV disease research agenda; (3) to
contribute to the immunology research agenda; and (4) to contribute to other
research agendas.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Collaboratory of AIDS Researchers for Eradication (CARE)
-
批准号:10313365
-
项目类别:
-
资助金额:$524.68万
-
财政年份:2021
-
负责人:DAVID M. MARGOLIS
-
依托单位:
Collaboratory of AIDS Researchers for Eradication (CARE)
-
批准号:10469441
-
项目类别:
-
资助金额:$524.68万
-
财政年份:2021
-
负责人:DAVID M. MARGOLIS
-
依托单位:
Collaboratory of AIDS Researchers for Eradication (CARE)
-
批准号:10624449
-
项目类别:
-
资助金额:$524.68万
-
财政年份:2021
-
负责人:DAVID M. MARGOLIS
-
依托单位:
Collaboratory of AIDS Researchers for Eradication (CARE)
-
批准号:9190915
-
项目类别:
-
资助金额:$459.3万
-
财政年份:2016
-
负责人:DAVID M. MARGOLIS
-
依托单位:
A Pilot Trial of the effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection
-
批准号:9022397
-
项目类别:
-
资助金额:$134.89万
-
财政年份:2015
-
负责人:DAVID M. MARGOLIS
-
依托单位:
The Role of Gamma Delta T Cells as Persistent Reservoirs of HIV Infection
-
批准号:9034786
-
项目类别:
-
资助金额:$49.89万
-
财政年份:2015
-
负责人:DAVID M. MARGOLIS
-
依托单位:
Martin Delaney Collaboratory to Eradicate HIV-1 Infection
-
批准号:8497418
-
项目类别:
-
资助金额:$848.64万
-
财政年份:2011
-
负责人:DAVID M. MARGOLIS
-
依托单位:
A Phase II/II Investigation of the Effect of Vorinostat (VOR) in HIV Infection
-
批准号:8144516
-
项目类别:
-
资助金额:$56.55万
-
财政年份:2011
-
负责人:DAVID M. MARGOLIS
-
依托单位:
Administrative Core
-
批准号:8202299
-
项目类别:
-
资助金额:$29.93万
-
财政年份:2011
-
负责人:DAVID M. MARGOLIS
-
依托单位:
Martin Delaney Collaboratory to Eradicate HIV-1 Infection
-
批准号:8298077
-
项目类别:
-
资助金额:$899.01万
-
财政年份:2011
-
负责人:DAVID M. MARGOLIS
-
依托单位:
Martin Delaney Collaboratory to Eradicate HIV-1 Infection
-
批准号:8707337
-
项目类别:
-
资助金额:$851.33万
-
财政年份:2011
-
负责人:DAVID M. MARGOLIS
-
依托单位:
A Phase II/II Investigation of the Effect of Vorinostat (VOR) in HIV Infection
-
批准号:8250335
-
项目类别:
-
资助金额:$56.52万
-
财政年份:2011
-
负责人:DAVID M. MARGOLIS
-
依托单位:
Martin Delaney Collaboratory to Eradicate HIV-1 Infection
-
批准号:8874860
-
项目类别:
-
资助金额:$709.65万
-
财政年份:2011
-
负责人:DAVID M. MARGOLIS
-
依托单位:
Martin Delaney Collaboratory to Eradicate HIV-1 Infection
-
批准号:8185798
-
项目类别:
-
资助金额:$638.02万
-
财政年份:2011
-
负责人:DAVID M. MARGOLIS
-
依托单位:
Studies in humans to delineate the basis for viral persistence
-
批准号:8326899
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2011
-
负责人:DAVID M. MARGOLIS
-
依托单位:
A Phase II/II Investigation of the Effect of Vorinostat (VOR) in HIV Infection
-
批准号:8447062
-
项目类别:
-
资助金额:$53.13万
-
财政年份:2011
-
负责人:DAVID M. MARGOLIS
-
依托单位:
HIV Latency, Epigenetics, and Therapeutics
-
批准号:8623117
-
项目类别:
-
资助金额:$59.76万
-
财政年份:2010
-
负责人:DAVID M. MARGOLIS
-
依托单位:
HIV Latency, Epigenetics, and Therapeutics
-
批准号:8111149
-
项目类别:
-
资助金额:$61.86万
-
财政年份:2010
-
负责人:DAVID M. MARGOLIS
-
依托单位:
HIV Latency, Epigenetics, and Therapeutics
-
批准号:8233452
-
项目类别:
-
资助金额:$61.14万
-
财政年份:2010
-
负责人:DAVID M. MARGOLIS
-
依托单位:
Mechanisms of chromatin regulation that drive HIV latency
-
批准号:8138949
-
项目类别:
-
资助金额:$40.49万
-
财政年份:2010
-
负责人:DAVID M. MARGOLIS
-
依托单位: